looking good, page-9

Hello crew.... me back in even more too!.... could not resist after that follow-up "update".... took what advantage I could of the sell-down topping up nicely.

Former weak hand... Guilty. Trust restored.

I believe the delay in Taylor Collison review is due to ATCOR management saying to hold off a little.... as these latest developments are able to be factored into the review's targets.

Am watching and waiting... nice to see seller so grumpy in his shake-out tactics.... a good sign that we are onto something well worth owning....

-----------------

Even our dear friends at Sydney Morning Herald are bullish on ATCOR.... tiny but extremely positive spin coming from SMH within the last 24 hours... can not wait to see that blue sky factored in by the market.

Link and article below....

-----------------

http://www.smh.com.au/business/marketing-outfit-shows-value-but-triggers-are-tricky-to-find-20130227-2f65m.html?skin=text-only


AtCor Medical Holdings

AT THE micro end of the market one of the better results this season came from AtCor (ACG), a medical device company that specialises in early detection of cardiovascular disease. The company posted a half-yearly profit of $2.3 million, well ahead of forecasts.

AtCor is highly unusual for an Australian medical development company with no blue sky embedded in the valuation. Refreshingly, the company has recently cut costs and states it will only ramp up expenditure when revenue is secured. This effectively means there will not be a major cash burn that is typically associated with other medical development outfits.

AtCor has a market value of $14 million and net cash on the balance sheet of $2.1 million. The first-half profit was boosted by a $700,000 grant and analysts are expecting a break-even result for the second half. Despite this, it is only trading at about seven times earnings.

The company supplies product for the clinical trials and research markets. Its devices measure central aortic blood pressure non-invasively for blood pressure and arterial stiffness.

There have been a number of recent encouraging signs for AtCor, including the US approval of the new SphygmoCor System Excel device. Not only is the device a quantum improvement in terms of functionality but it has also been granted a reimbursement code for clinicians. The addressable market is estimated at $US100 million a year. On this segment alone the firm could easily be valued 50 per cent higher at 22¢ a share.

----------------------

May explain some of the nice looking early bids??? Let's see if they last.

bsh